The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Wirkung von GLP-1-Rezeptoragonisten auf metabolische Entzündungsmarker bei Patient:innen mit Typ-2-Diabetes mellitus: systematische Übersicht und Metaanalyse
PeerJ · 03.02.2026 · 14 · e20710
DOI: 10.7717/peerj.20710 ↗Auf einen Blick
Die Metaanalyse zeigt bei Typ-2-Diabetes unter GLP-1-Rezeptoragonisten eine Senkung von CRP und TNF-α. Für IL-6 ergab sich kein signifikanter Effekt.
Fragestellung
Welchen Einfluss haben GLP-1-Rezeptoragonisten auf metabolische Entzündungsmarker bei Patient:innen mit Typ-2-Diabetes mellitus?
Methode
Systematische Übersicht und Metaanalyse nach PRISMA; Suche in PubMed, EBSCO, Embase, Web of Science und Cochrane Library; Subgruppenanalysen zu Subtypen, Dauer und Häufigkeit.
Ergebnisse
25 Studien mit 1.878 Teilnehmenden. CRP sank in 18 Studien: SMD −0,39 (95 %-KI −0,72 bis −0,06; P = 0,02; I2 = 88%). TNF-α sank in 14 Studien: SMD −0,51 (95 %-KI −0,81 bis −0,20; P = 0,001; I2 = 81%). IL-6 war nicht signifikant verändert.
Einschränkungen
Heterogenität hoch für CRP, IL-6 und TNF-α (I2 88 %, 96 %, 81 %).
Schlussfolgerung der Autor:innen
GLP-1-Rezeptoragonisten zeigen bei T2DM eine gewisse antiinflammatorische Wirkung und senken CRP und TNF-α; der Effekt hängt offenbar von Wirkstofftyp und Behandlungsdauer ab.
Kernaussagen
- CRP und TNF-α nahmen unter GLP-1-Rezeptoragonisten signifikant ab.
- IL-6 zeigte nur einen nicht signifikanten Abwärtstrend.
- Stärkere Effekte bei bestimmtem Wirkstofftyp und längerer Behandlung.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift PeerJ, online erschienen am 03.02.2026. Verfasst von Fang Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sports Teaching and Research, Lanzhou University, Lanzhou, GanSu, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Inflammation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
This study aimed to evaluate the impact of GLP-1 receptor agonists (GLP-1 RAs) on metabolic inflammatory markers in patients with type 2 diabetes mellitus (T2DM), providing evidence-based insights for their potential application in anti-inflammatory therapy.
Methods
Research questions were developed using the PICOS framework, and the study strictly adhered to PRISMA guidelines. Comprehensive literature searches were conducted across PubMed, EBSCO, Embase, Web of Science, and the Cochrane Library. Data synthesis and subgroup analyses (focusing on GLP-1 RA subtypes, treatment duration, and administration frequency) were performed using RevMan 5.4 software.
Results
Out of 1,347 articles retrieved, 25 studies were ultimately included, comprising a total sample of 1,878 participants (879 in the experimental groups and 999 in the control groups). Quality assessment indicated that most studies exhibited a low risk of bias, with only one study rated as high risk and three studies showing some concerns. Meta-analysis results demonstrated that 18 studies reported a significant reduction in CRP levels in T2DM patients treated with GLP-1 RAs (SMD = −0.39, 95% CI [−0.72 to −0.06], P = 0.02, I 2 = 88%). Although the results from 13 studies indicated a decreasing trend in IL-6 levels (SMD = −0.52), this change was not statistically significant (95% CI [−1.34 to 0.29], P = 0.21, I 2 = 96%). Additionally, 14 studies showed that GLP-1 RAs significantly reduced TNF- α levels (SMD = −0.51, 95% CI [−0.81 to −0.20], P = 0.001, I 2 = 81%). Subgroup analyses revealed that both the type of GLP-1 RA and a longer treatment duration (≥36 weeks) were associated with more pronounced improvements in inflammatory markers.
Conclusion
GLP-1 RAs exhibit a certain degree of anti-inflammatory effect in patients with T2DM, effectively reducing CRP and TNF- α levels. The anti-inflammatory efficacy appears to be influenced by both the type of drug used and the duration of treatment, with more pronounced effects observed for specific drug classes and with longer treatment periods. These findings provide further evidence supporting the use of GLP-1 RAs in the anti-inflammatory management of T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sports Teaching and Research, Lanzhou University, Lanzhou, GanSu, China.
- School of Physical Education, Southwest Medical University, Luzhou, Sichuan, China.
- School of Physical Education, Huzhou University, Huzhou, Zhejiang, China.
- Faculty of Health Sciences and Sports, Macao Polytechnic University, Macao, China.
- School of Physical Education, Zhejiang Guangsha Vocational and Technical University of Construction, Dongyang, Zhejiang, China.
Zitieren
APA
Zhao, F., Wang, H., Li, S., Yun, H., & Su, W. (2026). The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. PeerJ, 14, e20710. https://doi.org/10.7717/peerj.20710
Vancouver
Zhao F, Wang H, Li S, Yun H, Su W. The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. PeerJ. 2026;14:e20710. doi:10.7717/peerj.20710
BibTeX
@article{Zhao2026,
author = {Zhao, Fang and Wang, Haoshu and Li, Shenguang and Yun, Hezhang and Su, Wenbo},
title = {The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e20710},
doi = {10.7717/peerj.20710}
}
EUVIMED